Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.35 USD
-0.03 (-1.06%)
Updated Aug 28, 2024 02:49 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Income Statements
Fiscal Year end for Cellectis SA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 26 | 67 | 82 | 23 |
Cost Of Goods | 1 | 2 | 31 | 36 | 11 |
Gross Profit | 8 | 24 | 36 | 46 | 12 |
Selling & Adminstrative & Depr. & Amort Expenses | 106 | 114 | 166 | 132 | 135 |
Income After Depreciation & Amortization | -97 | -90 | -131 | -85 | -124 |
Non-Operating Income | 21 | 9 | 13 | 5 | 12 |
Interest Expense | 41 | 18 | 8 | 18 | 4 |
Pretax Income | -116 | -99 | -125 | -97 | -115 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -7 | -8 | -11 | -16 | -13 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -117 | -99 | -125 | -97 | -115 |
Extras & Discontinued Operations | 8 | -15 | 0 | 0 | 0 |
Net Income (GAAP) | -101 | -106 | -114 | -81 | -102 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -79 | -71 | -114 | -76 | -117 |
Depreciation & Amortization (Cash Flow) | 19 | 18 | 17 | 10 | 7 |
Income After Depreciation & Amortization | -97 | -90 | -131 | -85 | -124 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 57.10 | 45.55 | 44.78 | 42.50 | 42.36 |
Diluted EPS Before Non-Recurring Items | -2.05 | -2.17 | -2.55 | -1.91 | -2.41 |
Diluted Net EPS (GAAP) | -1.77 | -2.33 | -2.55 | -1.91 | -2.41 |
Fiscal Year end for Cellectis SA falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 9.50 | 6.50 | 1.99 | 1.64 | 2.00 |
Cost Of Goods | 0.00 | 0.00 | 0.17 | 0.18 | 0.06 |
Gross Profit | 9.50 | 6.50 | 1.82 | 1.46 | 1.95 |
SG&A, R&D, and Dept/Amort Expenses | 26.72 | 27.39 | 31.37 | 22.13 | 25.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.22 | -20.89 | -29.55 | -20.67 | -23.65 |
Non-Operating Income | 8.40 | 29.41 | -16.48 | 4.92 | 32.27 |
Interest Expense | 16.65 | 3.14 | 17.56 | 1.62 | 16.28 |
Pretax Income | -25.46 | 5.38 | -63.58 | -17.38 | -7.68 |
Income Taxes | -0.19 | -0.26 | 0.01 | 0.11 | 0.26 |
Minority Interest | 0.00 | 0.00 | -2.00 | 0.00 | -2.94 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -25.27 | 5.64 | -63.59 | -17.48 | -7.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 18.73 | 0.00 | -5.65 |
Net Income (GAAP) | -25.27 | 5.64 | -42.85 | -17.48 | -10.65 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 89.85 | 103.09 | 65.31 | 56.39 | 55.58 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.15 | -0.64 | -0.31 | -0.14 |
Diluted Net EPS (GAAP) | -0.28 | -0.15 | -0.69 | -0.31 | -0.19 |